Geron Corporation (GERN)
NASDAQ
Market Cap
$2.64B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
339 of 809
Rank in Industry
205 of 445
Largest Insider Buys in Sector
GERN Stock Price History Chart
GERN Stock Performance
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Activity of Geron Corporation
Over the last 12 months, insiders at Geron Corporation have bought $30,064 and sold $5.82M worth of Geron Corporation stock.
On average, over the past 5 years, insiders at Geron Corporation have bought $22,764 and sold $6.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: O'Farrell Elizabeth G. (director) — $30,064.
The last purchase of 13,186 shares for transaction amount of $30,064 was made by O'Farrell Elizabeth G. (director) on 2023‑08‑24.
List of Insider Buy and Sell Transactions, Geron Corporation
| 2024-06-10 | Sale | Kapur Anil | EVP, Corp Strategy & CCO | 421,875 0.0656% | $4.64 | $1.96M | -7.54% | |
| 2024-06-10 | Sale | Feller Faye | EVP, Chief Medical Officer | 287,900 0.0446% | $4.63 | $1.33M | -7.54% | |
| 2024-06-04 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 600,000 0.1014% | $4.00 | $2.4M | +16.08% | |
| 2024-05-15 | Sale | LAWLIS V BRYAN | director | 35,000 0.0057% | $3.75 | $131,250 | +2.05% | |
| 2023-08-24 | O'Farrell Elizabeth G. | director | 13,186 0.0022% | $2.28 | $30,064 | -6.71% | ||
| 2023-05-11 | Sale | LAWLIS V BRYAN | director | 35,000 0.0067% | $3.00 | $105,000 | -20.42% | |
| 2023-05-01 | Sale | Molineaux Susan | director | 35,000 0.0062% | $2.48 | $86,800 | -10.16% | |
| 2023-02-10 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,668 0.0818% | $3.00 | $1.34M | -23.26% | |
| 2023-02-09 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0826% | $3.03 | $1.35M | -22.92% | |
| 2023-02-09 | Sale | GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 384,719 0.0711% | $3.03 | $1.17M | -22.92% | |
| 2023-02-08 | Sale | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 400,000 0.0742% | $3.08 | $1.23M | -23.44% | |
| 2023-02-08 | Sale | SCARLETT JOHN A | Chairman, President and CEO | 446,666 0.0828% | $3.08 | $1.38M | -23.44% | |
| 2020-08-21 | O'Farrell Elizabeth G. | director | 17,441 0.0056% | $1.73 | $30,173 | 0.00% | ||
| 2020-01-10 | O'Farrell Elizabeth G. | director | 6,000 0.0029% | $1.34 | $8,056 | +23.36% | ||
| 2019-04-09 | Sale | BEHRS MELISSA KELLY | EVP, Chief Business Officer | 241,270 0.1421% | $2.00 | $482,540 | -23.08% | |
| 2018-09-13 | Sale | Spiegel Robert J. | director | 70,000 0.046% | $6.85 | $479,500 | -73.67% | |
| 2018-08-24 | Sale | ROSENFIELD STEPHEN | EVP, Genl Counsel & Secretary | 75,000 0.0354% | $4.51 | $338,250 | -70.71% | |
| 2015-05-29 | Sale | BEHRS MELISSA KELLY | EVP BD and Port&Alliance Mgmt | 4,760 0.003% | $3.84 | $18,278 | -14.77% | |
| 2015-05-29 | Sale | Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 4,760 0.003% | $3.84 | $18,278 | -14.77% | |
| 2015-03-18 | Sale | Hofstaetter Thomas | director | 140,000 0.0895% | $4.10 | $574,000 | -6.14% |
Insider Historical Profitability
13.15%
| O'Farrell Elizabeth G. | director | 26220 0.0048% | $4.45 | 3 | 0 | +11.68% |
| Kapur Anil | EVP, Corp Strategy & CCO | 0 0% | $4.45 | 0 | 1 | |
| Feller Faye | EVP, Chief Medical Officer | 0 0% | $4.45 | 0 | 1 | |
| LAWLIS V BRYAN | director | 0 0% | $4.45 | 0 | 2 | |
| SCARLETT JOHN A | Chairman, President and CEO | 600000 0% | $4.45 | 2 | 4 | <0.0001% |
| MERIX BIOSCIENCE INC | 10 percent owner | 4541100 0.8362% | $4.45 | 0 | 7 | |
| GREENWOOD DAVID | President, Interim CEO, CFO | 754031 0.1388% | $4.45 | 0 | 15 | |
| LEBKOWSKI JANE | SVP, Chief Scientific Officer | 568154 0.1046% | $4.45 | 0 | 10 | |
| Kelsey Stephen Michael | EVP, R&D Head, CMO | 473122 0.0871% | $4.45 | 0 | 4 | |
| EARP DAVID | SVP, Corp Transactions | 467406 0.0861% | $4.45 | 0 | 11 | |
| OKARMA THOMAS | President and CEO | 437060 0.0805% | $4.45 | 0 | 8 | |
| Spink Katharine E. | SVP Alliance Mgmt & Operations | 328561 0.0605% | $4.45 | 0 | 6 | |
| KILEY THOMAS | director | 314059 0.0578% | $4.45 | 2 | 0 | <0.0001% |
| BRADBURY DANIEL | director | 142776 0.0263% | $4.45 | 1 | 0 | +67.22% |
| Bloom Olivia Kyusuk | EVP, Chief Financial Officer | 74588 0.0137% | $4.45 | 0 | 7 | |
| HARLEY CALVIN | VP, CSO Telomerase Tech | 69036 0.0127% | $4.45 | 0 | 10 | |
| Spiegel Robert J. | director | 65576 0.0121% | $4.45 | 0 | 1 | |
| WALKER JOHN PETER | director | 39119 0.0072% | $4.45 | 0 | 1 | |
| Benedetti Fabio M | SVP, Chief Med Off, Oncology | 38060 0.007% | $4.45 | 0 | 2 | |
| Hofstaetter Thomas | director | 26564 0.0049% | $4.45 | 0 | 1 | |
| STEIN ROBERT B | director | 0 0% | $4.45 | 0 | 3 | |
| Molineaux Susan | director | 0 0% | $4.45 | 0 | 1 | |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | 0 0% | $4.45 | 0 | 1 | |
| ROSENFIELD STEPHEN | EVP, Genl Counsel & Secretary | 0 0% | $4.45 | 0 | 1 | |
| BEHRS MELISSA KELLY | EVP, Chief Business Officer | 0 0% | $4.45 | 0 | 20 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $152.47M | 7.79 | 46.2M | 0% | +$0 | 0.15 | |
| BlackRock | $136.67M | 6.98 | 41.41M | -1.8% | -$2.5M | <0.01 | |
| State Street | $104.29M | 5.33 | 31.6M | +23.33% | +$19.73M | <0.01 | |
| Deep Track Capital Lp | $100.67M | 5.14 | 30.51M | +3.12% | +$3.04M | 0.46 | |
| The Vanguard Group | $98.57M | 5.04 | 29.87M | +4.57% | +$4.31M | <0.01 | |
| Vivo Capital | $89.84M | 4.59 | 27.23M | +12.76% | +$10.17M | 7.91 | |
| Tcg Crossover Management Llc | $57.39M | 2.93 | 17.39M | -25.6% | -$19.75M | 0.09 | |
| OrbiMed | $42.55M | 2.17 | 12.89M | +2,558.48% | +$40.95M | 0.87 | |
| Nea Management Company Llc | $42.16M | 2.15 | 12.78M | -43.91% | -$33M | 0.48 | |
| Fidelity Investments | $42.11M | 2.15 | 12.76M | +81.45% | +$18.9M | <0.01 | |
| Geode Capital Management | $37.71M | 1.93 | 11.43M | +4.41% | +$1.59M | <0.01 | |
| Wellington Management Company | $36.11M | 1.85 | 10.94M | +15.37% | +$4.81M | 0.01 | |
| Bioimpact Capital Llc | $34.57M | 1.77 | 10.48M | -2.24% | -$791,818.51 | 5.6 | |
| Logos Global Management Lp | $29.7M | 1.52 | 9M | New | +$29.7M | 3.19 | |
| Farallon Capital | $24.73M | 1.26 | 7.5M | New | +$24.73M | 0.17 | |
| Millennium Management LLC | $24.1M | 1.23 | 7.3M | -50.43% | -$24.51M | 0.02 | |
| Adage Capital Partners Gp L L C | $23.76M | 1.21 | 7.2M | New | +$23.76M | 0.04 | |
| Fairmount Funds Management LLC | $22M | 1.12 | 6.67M | New | +$22M | 2.4 | |
| Boxer Capital, LLC | $19.8M | 1.01 | 6M | +100% | +$9.9M | 0.99 | |
| Invesco | $18.05M | 0.92 | 5.47M | +25.43% | +$3.66M | <0.01 | |
| Northern Trust | $16.59M | 0.85 | 5.03M | -1.74% | -$294,254.40 | <0.01 | |
| Segall Bryant & Hamill | $14.68M | 0.75 | 4.45M | +0.66% | +$95,950.80 | 0.28 | |
| Goldman Sachs | $14.49M | 0.74 | 4.39M | +38.05% | +$3.99M | <0.01 | |
| Charles Schwab | $12.84M | 0.66 | 3.89M | +1.23% | +$155,944.80 | <0.01 | |
| Morgan Stanley | $11.07M | 0.57 | 3.35M | -68.25% | -$23.79M | <0.01 | |
| Balyasny Asset Management Llc | $10.36M | 0.53 | 3.14M | New | +$10.36M | 0.03 | |
| Samlyn Capital, LLC | $10.28M | 0.53 | 3.11M | New | +$10.28M | 0.18 | |
| Ally Bridge Group | $9.11M | 0.47 | 2.76M | -7.11% | -$696,768.59 | 5.12 | |
| Affinity Asset Advisors | $8.25M | 0.42 | 2.5M | New | +$8.25M | 1.47 | |
| Rafferty Asset Management Llc | $7.96M | 0.41 | 2.41M | +44.46% | +$2.45M | 0.02 | |
| Citigroup | $7.1M | 0.36 | 2.15M | +202.12% | +$4.75M | 0.01 | |
| T. Rowe Price | $6.82M | 0.35 | 2.06M | +999.68% | +$6.2M | <0.01 | |
| JPMorgan Chase | $6.6M | 0.34 | 2M | +15.02% | +$861,775.28 | <0.01 | |
| UBS | $5.96M | 0.31 | 1.81M | +25.37% | +$1.21M | <0.01 | |
| Russell Investments Group Ltd | $5.78M | 0.3 | 1.75M | +41.49% | +$1.69M | 0.01 | |
| Laurion Capital Management LP | $5.5M | 0.28 | 1.67M | New | +$5.5M | 0.15 | |
| BNY Mellon | $5.28M | 0.27 | 1.6M | -9.62% | -$562,339.83 | <0.01 | |
| Nuveen | $4.95M | 0.25 | 1.5M | +0.7% | +$34,349.70 | <0.01 | |
| Deutsche Bank | $4.46M | 0.23 | 1.35M | -80.87% | -$18.86M | <0.01 | |
| Bridger Management Llc | $4.42M | 0.23 | 1.34M | New | +$4.42M | 1.99 | |
| Nan Fung Group | $4.37M | 0.22 | 1.32M | +44.99% | +$1.36M | 4.75 | |
| Artal Group S A | $4.23M | 0.22 | 1.28M | New | +$4.23M | 0.02 | |
| Woodline Partners LP | $4.01M | 0.21 | 1.21M | New | +$4.01M | 0.04 | |
| Readystate Asset Management Lp | $3.93M | 0.2 | 1.19M | New | +$3.93M | 0.22 | |
| Saturn V Capital Management Llc | $3.71M | 0.19 | 1.12M | New | +$3.71M | 1.49 | |
| Kennedy Capital Management Inc | $3.71M | 0.19 | 1.13M | -0.87% | -$32,719.50 | 0.08 | |
| Mml Investors Services Llc | $3.48M | 0.18 | 1.05M | -18.67% | -$797,868.29 | 0.02 | |
| Citadel Advisors LLC | $3.25M | 0.17 | 986,109 | +53.32% | +$1.13M | <0.01 | |
| Bank of America | $3.18M | 0.16 | 963,293 | +76.17% | +$1.37M | <0.0001 | |
| Swiss National Bank | $2.65M | 0.14 | 804,300 | +3.97% | +$101,310.00 | <0.01 |